ALK(002940)2024-12-23 01:17Group 1: Product Selection and Pricing - Aidi Bone Calcitonin Soft Capsules were selected in the 10th batch of national centralized procurement, with a selected specification of 0.75μg7 capsules per box and a price of 5.04 CNY per box. This product is primarily used for treating osteoporosis, specifically postmenopausal osteoporosis [9]. - The company’s compound α-keto acid tablets were also selected in the 10th batch of national centralized procurement, with a selected specification of 0.63g24 tablets per box and a price of 8.52 CNY per box [11]. Group 2: Sales Performance - The sales volume and price of Zuo Yi have been affected by the national procurement results from the previous year and the "Four Consistencies" policy this year, leading to a decline in sales [9]. - In the third quarter of this year, the company reported an operating income of 274 million CNY, a decrease of 20.23% compared to the same period last year. The net profit attributable to shareholders was -18.16 million CNY, a decline of 426.40% year-on-year [10]. Group 3: Research and Development - The company has significantly increased its R&D expenses, with the third quarter R&D expenditure reaching 62.55 million CNY, an increase of 18.20 million CNY year-on-year [10]. - The company is focusing on transitioning from traditional generics to improved new drugs and innovative drugs to enhance its core competitiveness [13]. Group 4: Market Dynamics - The market for cephalosporin raw materials is expected to fluctuate based on upstream conditions, particularly the price and competitive landscape of penicillin industrial salt [9]. - The company’s main cephalosporin products have shown continuous growth in sales during the first three quarters of the year [9]. Group 5: Future Prospects - The company plans to continue expanding the market for Zuo Yi outside of national procurement and leverage its existing brand influence [9]. - The company has initiated preliminary research on the penicillin enzyme method project and will disclose information promptly if the project is confirmed for implementation [10].